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ThyX is an essential thymidylate synthase that is mechanistically and
structurally unrelated to the functionally analogous human enzyme, thus
providing means for selective inhibition of bacterial growth. To identify
novel compounds with anti-bacterial activity against the human pathogenic
bacterium Helicobacter pylori, based on our earlier biochemical and structural
analyses, we designed a series of eighteen 2-hydroxy-1,4-naphthoquinones
(2-OH-1,4-NQs) that targetHpThyX. Our lead-like molecules markedly inhib-
ited the NADPH oxidation and 20-deoxythymidine-50-monophosphate-
forming activities of HpThyX enzyme in vitro, with inhibitory constants in
the low nanomolar range. The identification of non-cytotoxic and non-
mitotoxic 2-OH-1,4-NQ inhibitors permitted testing their in vivo efficacy in a
mouse model for H. pylori infections. Despite the widely assumed toxicity of
naphthoquinones (NQs), we identified tight-binding ThyX inhibitors that
were tolerated in mice and can be associated with a modest effect in reducing
the number of colonizing bacteria. Our results thus provide proof-of-concept
that targeting ThyX enzymes is a highly feasible strategy for the development
of therapies against H. pylori and a high number of other ThyX-dependent
pathogenic bacteria. We also demonstrate that chemical reactivity of NQs
does not prevent their exploitation as anti-microbial compounds, particula-
rly when mitotoxicity screening is used to prioritize these compounds for
further experimentation.1. Introduction
De novo synthesis of 20-deoxythymidine-50-monophosphate (dTMP or thymidy-
late) is essential for cellular survival. Consequently, inhibiting the methylation
reaction of 20-deoxyuridine-50-monophosphate (dUMP) to dTMP by thymidylate
synthases (TS) provides a powerful means for controlling the growth of eukaryotic
or bacterial cells. This is illustrated by the development of several chemotherapeu-
tic agents that target thymidylate biosynthesis. For instance, fluoropyrimidines
(e.g. 5-fluorouracil and capecitabine) and antifolates (e.g. methotrexate and
pemetrexed), which target human TS, are successful drugs used in cancer che-
motherapy [1]. Moreover, methotrexate and trimethoprim target dihydrofolate
reductase (DHFR) that is also required for efficient thymidylate synthesis in
many eukaryotes, including pathogenic parasites and bacteria [2,3].
Human TS belongs to the ThyA family of enzymes (EC 2.1.1.45) that uses
N5,N10-methylene-5,6,7,8-tetrahydrofolate (CH2H4folate) in a reductive methyl-
ation reaction [4]. In this reaction, tetrahydrofolate (H4folate) reduces the
methylenemoiety after its transfer to the uracil ring, thus resulting in the formation
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ThyX proteins (EC 2.1.1.148; flavin-dependent thymidylate
synthase), uses a non-covalently bound flavin adenine dinu-
cleotide (FAD) cofactor to facilitate hydride transfer from
NAD(P)H [5–8]. Consequently, the end product of ThyX cata-
lysis is H4folate, explaining why ThyX-containing bacteria
(30% of all bacterial species) do not require DHFR FolA that
recycles H2folate to H4folate in actively dividing thyA-carrying
cells [9,10].
Several observations have established essential ThyX pro-
teins as highly relevant drug targets [11–13]. They are found
in a large number of human pathogenic bacteria (electronic
supplementary material, table S1), including Helicobacter
pylori (HpThyX) and Mycobacterium tuberculosis (MtbThyX),
but are absent in humans. Moreover, the structure and mech-
anisms of ThyA and ThyX proteins are strikingly different, a
fact that greatly facilitates the development of specific ThyX
inhibitors that do not act on human TS [11–14]. The key fea-
ture of the active site of ThyX proteins is its location in a large
and flexible cavity at the interface of three subunits of the
ThyX homotetramer. This location allows surface exposure of
the N5 atom of the flavine isoalloxazine ring that, at the milli-
second time scale, is involved in hydride transfer [15]. As the
hydride transfer to ThyX-bound FAD from NAD(P)H is either
strictly dependent on or activated by the nucleotide substrate
dUMP, this renders ThyX inhibitors that are competitive with
respect to dUMP selective within the bacterial cell. Indeed, we
previously identified non-substrate-based, tight-binding ThyX
inhibitors that inhibited growth of genetically modified Escheri-
chia coli cells carrying thyX. The observed pattern of inhibition
mimics a genetic knockout of TS [11], indicating selective
in vivo targeting. The co-crystal structure of one such inhibitor—
2-hydroxy-3-(4-methoxybenzyl)-1,4-naphthoquinone (themole-
cule C8-C1)—revealed binding within the conserved active site,
partially overlapping with the dUMP-binding pocket. In
addition to our inhibitor studies on ThyX proteins, several
dUMPanalogues have also beendescribed that inhibitMtbThyX
at micromolar concentrations [12,13,16]. Importantly, recent
studies have also indicated that 5-fluoro-dUMP, a metabolite
of fluorouracil, selectively inhibits ThyX in living cells of
M. tuberculosis [17].
The fact that naphthoquinones (NQs) inhibit ThyX proteins
is of great interest, as biological activities of these compounds
are widely reported. For instance, the anti-cancer activity
of plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone), a
natural naphthoquinone derivative isolated from Plumbago or
Dyospiro sp., has been observed in cell cultures, as well as in
animal models [18,19]. This molecule and dyospirin (a dimeric
analogue of plumbagin) have also shown anti-microbial
activity against different pathogens, including M. tuberculosis
[20–22]. Moreover, atovaquone (2-(trans-4-(P-chlorophenyl)-
cyclohexyl)-3-hydroxy-1,4-naphthoquinone), a well-known
2-OH-1,4-NQ (Malarone, GlaxoSmithKline), targets the
respiratory electron transfer chain, and is clinically used in
anti-pneumocystis, anti-toxoplasmosis and anti-malarial treat-
ments [23]. Recently, NQ-based inhibitors of DNA gyrasewith
a novel mechanism of action have also been described [24].
Despite these remarkable observations, the further use of
NQs in biomedical applications has been hindered by their
redox activity and widely assumed toxicity [25–28].
The first flavin-dependent TS to be biochemically charac-
terized was the ThyX enzyme from H. pylori [9]. This spiral-
shaped, Gram-negative bacterium infects the gastric mucosaof about half of the world’s population, and is associated
with chronic gastritis, peptic ulcers and gastric carcinoma
[29]. Here, we report on the identification of the new 2-OH-
1,4-NQ derivatives with relatively low cyto- and mitotoxicity.
These molecules display a potent inhibition of H. pylori ThyX
activity. Some of these ThyX inhibitors are well tolerated, and
one of them has shown modest but significant activity in an
animal model of infection. We expect that our results will not
only significantly speed up thymidylate synthase-based anti-
microbial discovery approaches, but will also increase the
interest in biological activities of NQs.2. Material and methods
2.1. Chemicals
The 2-OH-1,4-NQ derivatives designed and used in this study
(figure 1a) were synthetized by Roowin (Riom, France).
Purity of the compounds (more than 95%) was confirmed by
HPLC analyses using detection at 254 nm. 1H NMR and
mass spectrometry (ESIþ) were used to confirm the conformity
of the synthetized molecules. Aqueous solubility (logSW) of
the compounds was estimated using the Yalkowsky formula
logSW ¼ 0.8–0.01(MP2 25)2 logP, with MP being an exper-
imentally determined melting point of the compound.
Concentrated stock solutions (10 mg ml21) of the different
compounds were prepared in dimethyl sulfoxide (DMSO).
For mouse infection and treatment, the compounds were dis-
solved in 2% b-cyclodextrine. All other chemicals were
purchased from Sigma-Aldrich: ampicillin (A0166), amphoter-
icin B (A4888), atovaquone (A7986), b-cyclodextrine (C4767),
DMSO (D2650), FAD (F6625), NADPH (N7505), polymyxin
B (P4932), rotenone (R8875), dUMP (D3876) and vancomycin
(V2002). CH2H4folate was provided by Eprova, Merck.
2.2. Helicobacter pylori strains and growth conditions
Helicobacter pylori strains used in this study were 26695 and the
mouse-adapted strain SS1 [30,31]. Helicobacter pylori strains
were grown on BloodAgar Base 2 (Oxoı¨d) plates supplemented
with 10% defibrinated horse blood, or in Brain Heart Infusion
liquidmedium (Oxoı¨d), supplementedwith 8% decomplemen-
ted fetal bovine serum (FBS; Invitrogen) with an antibiotic–
fungicide mix consisting of vancomycin (final concentration
12.5 mg ml21), polymyxin B (0.31 mg ml21) and amphotericin
B (2.5 mg ml21). Helicobacter pylori was grown at 378C under
microaerophilic conditions obtained using the CampyGen
system (Oxoı¨d).
2.3. Cytotoxicity and mitotoxicity of 2-OH-1,4-NQ
compounds
Cytotoxicity of the 2-OH-1,4-NQ derivatives was assessed by
measuring lactate dehydrogenase (LDH) release following
manufacturer’s instructions (Cytotoxicity Detection Kit; Roche
Applied Sciences). Briefly, AGS cells (human gastric adenocar-
cinoma cell line; ATCC Catalog no. CRL-1739TM) were
cultured in Ham’s F-12 K medium containing 1% of FBS.
A total of 3  104 cells were added per well in a sterile
96-well tissue culture plate. Cells were then treated with differ-
ent doses of 2-OH-1,4-NQ compounds ranging from 0.78 to
50 mg ml21. After a 24 h incubation at 378C (5% CO2, 90%
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Figure 1. (a) Chemical structures of 2-OH-1,4-NQ derivatives tested in this study. Asterisk refers to the fact that molecule 010-G has a chloride (and not hydroxyl) at
position 2. (b) Chemical structure of 2-(trans-4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone (atovaquone). (c) Predicted logS values (aqueous solu-
bility) of the different drugs versus their molecular weight (g mol21). The four molecules selected for in vitro testing (figure 4) and for mouse experiments (figure
6) are indicated above their symbol (filled squares). Atov, atovaquone.
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and the supernatants were carefully removed and transferred
into optically clear 96-well microplates (Greiner Bio-One). The
dye solution containing iodotetrazolium chloride and sodium
lactate was then added to each well to quantify the amount of
LDH released into the extracellular medium. LDH was quanti-
fied by measuring the A490 using a PowerWave Microplate
Spectrophotometer (BioTek).Mitochondrial toxicity (mitotoxicity) was assessed by mea-
suring resazurin (7-hydroxy-3H-phenoxazin-3-one 10-oxide)
reduction by following absorption changes at 570 nm
(Mitochondrial Viability Assay; Abcam). Resazurin is an indi-
cator dye that reports on oxidation–reduction reactions taking
place in the mitochondria of living cells. AGS cells (ﬃ2.5  105
cells well21) cultured in a DMEM galactose/glutamine-
supplemented medium were seeded in sterile white-walled
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ent doses of 2-OH-1,4-NQ compounds ranging from 0.78 to
50 mg ml21. Addition of the stain solution was followed by a
further 4 h incubation at 378C (5% CO2, 90% humidity) and
A570wasmeasured. Rotenone, an inhibitor of themitochondrial
respiratory chain complex I, was used as a positive control.
2.4. Anti-microbial susceptibility testing: disc diffusion
method and minimal inhibitory concentration
values
The in vitro anti-bacterial activity of 2-OH-1,4-NQ com-
pounds was assessed against the 26695 and SS1 strains of
H. pylori. DMSO was used as control in all experiments.
Disc diffusion tests were performed in triplicate, includ-
ing a DMSO-only control on each plate, as specified in
the electronic supplementary material. Minimal inhibitory
concentrations (MICs) were determined using a broth micro-
dilution test in 24-well microtitre plates. For test inocula, an
overnight preculture of H. pylori strains 26695 and SS1 was
diluted to an OD600 of approximately 0.1 and 0.5 ml of this
suspension was transferred to each well. Ten microlitres of
twofold serial dilutions of each compound in DMSO, ranging
in concentration from 0.625 to 20 mg ml21, were added and
the covered plates were incubated for 24 h at 378C with orbi-
tal shaking at 140 r.p.m. under microaerophilic conditions.
The MIC was determined as the lowest compound concen-
tration resulting in full growth inhibition after 24 h of
incubation. All the tests were done in triplicate, including
cell-free and DMSO-only controls.
To determine the bactericidal activity of C8-C1 against
H. pylori, liquid BHI medium was inoculated with an over-
night culture of H. pylori 26695 at an initial OD600 of 0.1.
C8-C1 or chloramphenicol, used as bacteriostatic control,
were added after 4 h of culture time at final concentrations
of 5 and 30 mg ml21. To determine the viable counts of
surviving bacteria (colony forming units, CFU), aliquots of
culture were then plated in triplicate on blood agar plates
after 3 and 24 h exposure.
2.5. Protein production and purification
Escherichia coli strain BL21 ( fhuA2 [lon] ompT gal [dcm] DhsdS),
carrying HpthyX on plasmid pGL2 under the control of a
pBAD promoter, was grown at 378C on solid or liquid
Luria Bertani medium [9]. This strain was used for overpro-
duction and purification of HpThyX tagged with six
histidine residues [32]. The protein was purified by affinity
chromatography on a 5ml resin HiTrap TALON column
(GE Healthcare) using a linear imidazole gradient. Imidazole
was removed using a PD-10 column (Bio-Rad). Concentrated
fractions were pooled and stored at 2808C in 30 mM HEPES
(pH 8.0), NaCl 300 mM, glycerol 10% (v/v). The concen-
tration of purified proteins was determined by the Bradford
method (Bio-Rad). A450 values were used to detect FAD
bound to purified ThyX proteins.
2.6. Thyx activity measurements
HpThyX activity was assessed by measuring either deproto-
nation of [5-3H]dUMP or NAPDH oxidation activities [11,32].In the tritium release (deprotonation) assays, typical reac-
tions contained 10 mM MgCl2, 10% (v/v) glycerol, 500 mM
FAD, 2 mM NADPH, 1 mM CH2H4Folate and 10 mM
b-mercaptoethanol in 50 mMHEPES (pH 8). Different concen-
trations of dUMP were also included in the reaction mixtures.
The specific activity of tritiated [5-3H]dUMP (diammonium
salt) stock was 15–30 Ci mmol21 (Moravek Biochemicals,
CA, USA). 2-OH-1,4-NQ derivatives were prepared at
100 mM in 1% DMSO. Reactions were initiated by adding the
enzyme (10 mM) and were stopped after 20 min incubation at
378C.
NADPH oxidation assays were performed at 378C in 96-
well plates (Greiner Bio-One). One hundredmicrolitres of reac-
tionmixture containedHEPES 50 mM (pH 8.6), NaCl 150 mM,
FAD 50 mM, b-mercaptoethanol 1.43 mM, NADPH 500 mM
and 10 mM of purifiedHpThyX. dUMP and 2-OH-1,4-NQ con-
centrations were varied across 12.5–200 mM and 0.3–100 mM,
respectively.Microtitre plateswere prepared and transferred to
the microplate reader Chameleon II (Hidex). The reactions
were started by automatically injecting NADPH into individ-
ual wells and ThyX activity was determined by following
a decrease in absorbance at 340 nm. A molar extinction
coefficient of 6220 M21 cm21 at 340 nm (1340) was used to
quantify NADPH oxidation. Samples with added DMSO
and enzyme-free reactions were used as positive and negative
controls, respectively.
2.7. Thyx docking methodology
The H. pylori ThyX protein structure (PDB code 3AH5 [33,34])
was processed by PYMOL software [35] to remove water
molecules and the C:dUMP cofactor. Polar hydrogen atoms
were added and atomic partial charges were assigned using
the PYMOL VINA plugin [36]. The residues A:Arg197,
C:Arg109 and C:Tyr110 were chosen to be flexible during
docking performed with the VINA software [37]. A cubic
search volume of 25  25  25A˚ centred on A:FAD N5 atom
was defined and the lowest predicted energy conformation
was kept for analysis.
2.8. Mouse infection and treatment
NMRI-specific pathogen-free mice (Charles River Labora-
tories) were orogastrically inoculated with 108 CFU of the
H. pylori mouse-adapted strain SS1, prepared in 100 ml of
peptone broth. Four groups of six to eight mice were infected
by H. pylori strain SS1. Earlier experiments have established
that after one week, colonization of mice is fully established
[38]. A negative control group of five mice was inoculated
with peptone broth alone and was not colonized by
H. pylori. One week after infection, three groups of mice
were treated orogastrically three times a day with 500 ml
of either compound 010-C, 010-E or 010-I dissolved in
2% b-cyclodextrin at 0.25 mg ml21 (0.375 mg mouse d21)
during one week. As a control, the fourth group of mice
was treated orogastrically three times a day by the same
amount of 2% b-cyclodextrin (17.6 mM), the vehicle of the
compounds. Administered particles had a hydrodynamic
radius of 180–200 nm and their size and monodispersity
were measured using dynamic light scattering (Malvern
Instruments, Zetasizer Nano-S instrument). This average
size is in agreement with the average size of b-cyclodextrin
particles that self-aggregate in water at a concentration of
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the mouse stomach, were enumerated by culture of serial
dilutions of homogenized tissue on blood agar plates
containing bacitracin (200 mg ml21) and nalidixic acid
(10 mg ml21) as in [40].Table 1. In vitro and biological activity of 2-OH-1,4-NQ compounds against
HpThyX and H. pylori, respectively.
molecule
inhibition
against
ThyX (%
remaining
activity
relative to
control)
minimal inhibitory
concentration (MIC)
strain 26695
(mg ml21)
(mM)
strain SS1
(mg ml21)
(mM)
007-A (C8C1) 38.5 10 (33.98) 10 (33.98)
007-B 60.2 10 (26.68) 10 (26.68)
007-C 62.5 5 (13.01) 5 (13.01)
007-D 45.7 20 (62.03) 20 (62.03)
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v
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Figure 2. Effect of C8-C1 on the in vitro growth of H. pylori strain 26695.
Chloramphenicol, a well-known bacteriostatic antibiotic, was used as control.
CFUs were determined after 3 h or 24 h exposure. The asterisk indicates that
no growth was observed.
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3.1. Optimization and custom-synthesis of new 2-OH-
1,4-NQ compounds
To identify novel compounds targeting the ThyX enzyme of
H. pylori (HpThyX), we designed a series of 2-OH-1,4-NQ
derivatives using the commercial molecule C8-C1 (or its
resynthesized version 007-A) as starting point (figure 1).
This molecule was identified earlier as selective ThyX inhibi-
tor with cellular activity against genetically modified E. coli
strains [11]. Mass spectrometry and 1H NMR analyses con-
firmed the molecular structures of the NQ derivatives
indicated in figure 1a. All molecules tested in further exper-
iments were more than 95% pure based upon HPLC
analyses using detection at 254 nm. Molecular weight and
predicted logP values of these molecules ranged from 230
to 375 Da and 1.85 to 5.2, respectively (electronic supplemen-
tary material, table S2). Aqueous solubility, a key factor
determining the ADME-Tox properties of small molecules,
was estimated using the Yalkowsky formula (see Material
and methods) relying on experimentally determined melting
points and calculated logP values. These calculations predict
that the aqueous solubility of the compounds varies from
40 mM to 2 mM (figure 1c). It is of note that most of these
molecules are predicted to be considerably more soluble
than the closely related atovaquone, a commercially availa-
ble anti-malarial compound targeting the mitochondrial
cytochrome bc1 complex (figure 1b,c).007-E 66.3 10 (35.42) 10 (35.42)
007-F 60.6 5 (15.06) 10 (15.06)
007-G 61.8 20 (56.16) 5 (14.04)
010-A 49.5 10 (33.48) 5 (16.74)
010-B 74.3 10 (33.30) 10 (33.30)
010-C 76.4 10 (39.34) 10 (39.34)
010-D 36.4 10 (37.00) 10 (37.00)
010-E 77.7 5 (14.27) 5 (14.27)
010-F 74.5 10 (31.58) 5 (15.79)
010-G 21.1 0.625 (2.07) 0.625 (2.07)
010-H 57.8 20 (64.45) 10 (32.23)
010-I 64.3 10 (43.42) 10 (43.42)
010-J 49.7 2.5 (8.49) 2.5 (8.49)
010-K 75.1 20 (61.67) 10 (30.84)3.2. Helicobacter pylori growth is inhibited by 2-OH-1,4-
NQ derivatives targeting HpThyX
Using semi-quantitative deprotonation assays that detect
proton release from [5-3H]dUMP during ThyX catalysis,
the effect of these 2-OH-1,4-NQ compounds against
HpThyX was investigated. Table 1 shows that all molecules
substantially inhibited ThyX activity at micromolar concen-
trations. The susceptibility of H. pylori to these compounds
was determined using the disc diffusion method (electronic
supplementary material, figure S2) and via the determination
of MICs (table 1; broth microdilution test). Overall, both tests
gave similar results, indicating anti-pylori activity against
both strains 26695 (wild-type strain) and SS1 (mouse-adapted
strain) at micromolar concentrations (typical MIC-values ran-
ging from 0.625 to 10 mg ml21). When H. pylori liquid
cultures were exposed to C8-C1 for up to 24 h, no viable
cells were recovered after replating on solid media lacking
this compound (figure 2), indicating that the anti-microbial
activity of the C8-C1 compound is bactericidal. Expectedly,
chloramphenicol behaved as bacteriostatic agent under these
conditions (figure 2). The molecule 010-G, where a hydroxyl
group at the position 2 was replaced with a chlorine, was
very active in liquid cultures (MIC  0.625 mg ml21), butinactive in disc diffusion tests, due to limited diffusion of the
compound from its filter.
3.3. In vitro cytotoxicity and mitotoxicity tests
NQs are known to possess biological activities against differ-
ent cell types, prompting us to investigate the possible
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as control. The cytotoxicity of the compounds was deter-
mined by measuring LDH release from AGS cells, a human
gastric adenocarcinoma cell line, as is detailed in Material
and methods. These experiments revealed that the majority
of the compounds are either non-cytotoxic in the concentration
range tested or are less cytotoxic than atovaquone, which at
25 mg ml21 had a cytotoxic effect of 48+5% (figure 3a; elec-
tronic supplementary material, figure S3A). This result is
similar to what has been described previously for atovaquone
in human hepatic HL-7702 cells [26]. The molecule 010-G with
a potent anti-microbial activity was found to be cytotoxic and
was not studied further in this study (electronic supplementary
material, figure S3).
The mitotoxicity of these compounds was assessed by
measuring NADPH/NADH-dependent resazurin reduction
by the mitochondria of living AGS cells (figure 3b). Rotenone
and atovaquone, which target complexes I and III of the
mitochondrial respiratory chain, respectively, were used
as positive controls. These experiments revealed that the
cytotoxic compounds identified above target the mitochon-
drial respiratory chain (electronic supplementary material,
figure S3B), whereas the non-cytotoxic inhibitors were also
found to be non-mitotoxic (figure 3).3.4. In vitro testing of 2-OH-1,4-NQ derivatives against
ThyX from Helicobacter pylori
To investigate the inhibitory potential of the molecules 007-A
(C8-C1), 010-C, 010-E and 010-I against HpThyX in more
detail, we used a quantitative tritium release assay (see
Material and methods). These molecules were chosen for
more detailed studies because they were found to be non-cytotoxic and non-mitotoxic in our assays. We first showed
that these molecules suppressed the dTMP-forming activity
at a compound concentration of 100 mM using 10 mM of
ThyX enzyme (figure 4a). Using the same set of compounds
in NADPH oxidation assays, our results revealed that IC50
values varied linearly as a function of the dUMP concen-
tration (figure 4b). The observed linear correlation with a
positive slope is indicative of the molecules tested acting as
tight-binding competitive inhibitors with respect to dUMP.
From the slope of these curves, we estimate Ki-values of
1000, 367, 258 and 28 nM for the molecules 010-E, C8-C1,
010-I and 010-C, respectively. Thus, our chemical series
allowed a 10-fold improvement of the inhibitor affinity
towards H. pylori ThyX proteins in comparison to the starting
molecule C8-C1. Overall, our data indicate that the relatively
small size and high lipophilicity of the R substitution at
position 3 favours optimal inhibition of H. pylori ThyX.
Molecular modelling of the inhibitory binding in the active
site of HpThyX (figure 5) shows that binding in the vicinity
of the catalytically crucial N5-atom of the FAD cofactor is
highly feasible.
3.5. Mouse infection and treatment
The in vivo efficacy of the molecules 010-C, 010-E and 010-I
was assessed by testing their effect on mouse colonization
by H. pylori (figure 6). The molecules were dissolved in
b-cyclodextrin at 2% adjusted to pH 7.5, a drug delivery
vehicle known to be harmless towards mice and H. pylori.
These non-mitotoxic molecules were chosen for animal exper-
iments not only because of their appropriate logS and logP
values for oral absorption, but also for their markedly
(a) (c)
(b) (d )
Figure 5. Three-dimensional modelling of HpThyX– inhibitor complexes using AUTODOCK VINA. FAD and HpThyX inhibitor are depicted in stick representations with
carbon, oxygen, nitrogen and fluorine atoms coloured in yellow, red, blue and green, respectively. The HpThyX surface is shown with carbon, oxygen, nitrogen and
sulfur atoms coloured grey, red, blue and yellow, respectively. Some amino acids were removed for clarity. Two orientations, separated by a 908 rotation along the y-
axis, are shown. (a) 007-A (C8-C1). (b) 010-C. (c) 010-E. (d ) 010-I.
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Figure 6. Gastric colonization of NMRI mice infected with H. pylori strain SS1
after treatment with three 2-OH-1,4-NQ compounds: 010-C, 010-E and 010-I.
Mice were sacrificed two weeks after inoculation, including one week of oro-
gastric treatment with the compounds. Each symbol corresponds to the
H. pylori colonization load in the gastric mucosa of a single mouse. Squares
correspond to infected mice treated with 2% b-cyclodextrin (vehicle control),
triangles, circles and diamonds refer to infected mice treated with compounds
010-I, 010-E and 010-C, respectively. The horizontal bars correspond to the
geometric mean calculated for each group of mice. The dashed horizontal
bar represents the detection limit of colonization. Differences in the bacterial
loads were statistically analysed by the Mann–Whitney test (GraphPad,
Prism), ***p, 0.01 (one-tail).
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C8-C1. A previously established mouse model for following
H. pylori infections was used for these experiments [40].
After an initial colonization period of one week, three
groups of mice were treated orogastrically three times a day
with 500 ml of compounds 010-C, 010-E or 010-I at
0.25 mg ml21 (0.375 mg mouse day21) during one additional
week. The dosage of these treatments was 17 mg kg21 of
body weight, which is the same order of magnitude as anti-
biotics used for anti-H. pylori treatments. As a control, agroup of mice was orogastrically treated with the same
amount of 2% b-cyclodextrin. None of the aforementioned
treatments affected either the body or stomach weight of
the mice (data not shown). After treatment, viable H. pylori,
colonizing the stomach of the different groups of mice,
were enumerated by culturing serial dilutions of homogen-
ized tissue (figure 6). We observed a statistically significant
(Mann–Whitney test, one-tail, p ¼ 0.0003) decrease of 1.22
log (17-fold) in the colonization loads (geometric means) of
mice that were treated with the molecule 010-I as compared
with the mice treated with the vehicle alone.4. Discussion
Helicobacter pylori infections are common, and are currently
treated by either a classical triple therapy consisting of a com-
bination of proton pump inhibitor (PPI) and two antibiotics,
among them clarythromycin, amoxicillin and metronidazole
or, alternatively, by the simultaneous administration of PPI,
bismuth, tetracycline and metronidazole. Resistance to all of
these antibiotics except amoxicillin is frequent among clinical
strains of H. pylori. For instance, in Europe, the resistance
rates for adults reach 17.5% for clarithromycin and 35% for
metronidazole, thus justifying the search for new anti-
microbial compounds with activity against H. pylori cells [41].
The TS from H. pylori and humans are mechanistically
and structurally very distinct, thus prompting for the devel-
opment of new anti-microbial compounds specifically
targeting HpThyX. Towards this goal, we designed a set of
eighteen 2-OH-1,4-NQ derivatives that are closely related to
atovaquone, a clinically used anti-malarial compound
(figure 1). Despite considerable variations in predicted solu-
bility, hydrophobicity and size (electronic supplementary
material, table S2), all 18 molecules acted as ThyX inhibitors
in vitro under semi-quantitative assay conditions (table 1).
Molecules 007-A (¼C8-C1), 010-C, 010-E and 010-I were
then selected for a more quantitative study (figure 4).
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inhibitors with nanomolar Ki-values and provided additional
insight into further optimization. In all the structural models
obtained (figure 5), the binding modes of the inhibitor and
dUMP are similar, thus providing a plausible explanation
for the simultaneous inhibition of NADPH oxidation and
deprotonation activities. Thus, this mechanism of inhibition
is not the result of the redox or chemical reactivity of NQs,
but rather a direct effect of blocking a binding of a catalytic
activator dUMP. Thus, binding of the inhibitor in the vicinity
of the FAD cofactor first prevents activation of the NADPH
oxidation/FAD reduction and, second, the binding of the
substrate that receives a carbon from CH2H4folate is blocked
[15]. The docked configuration for the molecules C8-C1 and
010-C is very similar to that observed in crystal structures
of the PBCV-1 enzyme [11].
We moreover demonstrated that these compounds have a
potent and concentration-dependent anti-microbial activity
against two different strains of H. pylori grown in liquid or
solid medium (MIC-values in the range 0.625–20 mg ml21;
table 1). In addition, this anti-microbial activity is bactericidal,
as the number of viable cells drastically diminished when
H. pylori cultures were continuously exposed to the molecule
C8-C1 (figure 2). To date, our attempts to identify mutants
that are resistant to these compounds were unsuccessful
when using compound concentrations that inhibit growth on
solid media, suggesting that these molecules may have several
targets in bacterial cells. To exclude that the biological activities
of our molecules simply resulted from non-specific redox
activity or chemical reactivity, we performed cytotoxicity
and mitotoxicity tests. These studies identified several new
2-hydroxy-1,4-naphthoquinones (2-OH-1,4-NQs) that were
substantially less cytotoxic than atovaquone and an order of
magnitude more potent HpThyX inhibitors than the founding
molecule C8-C1. We also showed that cytotoxic 2-OH-1,4-NQs
(including atovaquone) targetedmitochondria in ourassays (elec-
tronic supplementarymaterial, figure S3). Interestingly,we found
that the compounds 010-C, 010-E, 010-I and C8-C1 activated the
mitochondrial metabolism at low concentrations (figure 3b),
suggesting that under these conditions these non-cytotoxic
compounds probably mediate electron transfer from NAD(P)H
to resazurin and/or might have antioxidant activity similar to
that of idebenone, a synthetic analogue of coenzyme Q10 [42].
The three compounds 010-C, 010-E and 010-I were chosen
for animal experimentation because of their lack of cytotox-
icity and high affinity against the target enzyme. To obtain
insight into the in vivo activity of these three HpThyXinhibitors, we investigated their effect in an H. pylori mouse
model of infection. This model has been used in previous
studies to validate the in vivo efficacy of H. pylori inhibitors.
Two studies used the same mouse model set-up and the
same H. pylori SS1 strain, one showing the in vivo efficacy
of a metronidazole treatment to eradicate H. pylori [43], and
a second one reporting the use of isopentenyloxycinnamyl
derivatives to reduce the H. pylori colonization loads [44].
Despite widely assumed toxicity of NQs, we found that the
three ThyX inhibitors tested were tolerated in mice. For the
molecule 010-I, with relatively high predicted solubility, a stat-
istically significant effect against whole cells of H. pylori was
identified using the aforementioned animal model (figure 6).
Although the observed in vivo effect remains modest (17-fold),
we consider our observations a promising starting point for
further small molecule optimization to improve, for example,
solubility and bioavailability of this class of compounds.
In summary,we have characterized a series of newHpThyX
inhibitors, allowing identification of non-mitotoxic NQs with
high efficiency against the target enzyme. Our results provide
proof-of-concept that targeting ThyX enzymes is a highly feas-
ible strategy for the development of therapies against H. pylori
and a high number of other ThyX-dependent pathogenic bac-
teria. Our results further underline that the widely assumed
chemical reactivity of NQs does not necessarily prevent their
exploitation as anti-microbial compounds, particularly when
mitotoxicity screening is used to prioritize these compounds
for further experimentation.Ethics. Experiments in mice were carried out in strict accordance with
the recommendations in the Specific Guide for the Care and the Use
of Laboratory Animals of the Pasteur Institute, according to the Euro-
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